OMICS International

International Conferences

Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series Ltd: World’s leading Event Organizer

 

Drug Labelling


As per available reports about 101 relevant journals, 28 Conferences, 28 workshops are presently dedicated exclusively to Drug Labelling and about 5000articles are being published on Drug Labelling

Drug Labeling current methods of naming, labelling, and packaging drug products are based on long-standing commercial considerations and bureaucratic procedures that tend to be insensitive to safety interests. These processes, which can appear arcane to outsiders, have been developed over a long period, are supported by substantial vested interests, and tend to resist change.  It is enlisted in Pharmacological Sciences, Ethics in Pharmacy, Current GMP Guidelines, Quality Control.

OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.

Scope and Importance:

Two key facts drive the pharmaceutical industry's approach to naming and labeling issues. First, the longer it takes from the date of patent issuance to the date a new drug is released for marketing, the fewer the number of years of sole ownership during which the manufacturer can maximize the return on its investment. All the time preceding FDA approval represents potential lost income to the company. Therefore, companies work to shorten the regulatory process and tend to vigorously oppose any new regulatory hurdle.

Current methods of naming, labelling, and packaging drug products are based on long-standing commercial considerations and bureaucratic procedures that tend to be insensitive to safety interests. These processes, which can appear arcane to outsiders, have been developed over a long period, are supported by substantial vested interests, and tend to resist change.

Two key facts drive the pharmaceutical industry's approach to naming and labelling issues. First, the longer it takes from the date of patent issuance to the date a new drug is released for marketing, the fewer the number of years of sole ownership during which the manufacturer can maximize the return on its investment. All the time preceding FDA approval represents potential lost income to the company. Therefore, companies work to shorten the regulatory process and tend to vigorously oppose any new regulatory hurdles.

Second, a company's investment in a new drug is significant and risky. Discovering and developing new drugs is difficult and expensive -- again, creating incentives to shorten and simplify the process wherever possible. Many different molecules must be synthesized to produce just one approved drug. Even after a company obtains a patent, the probability that a marketable drug will result is only 1-2%.

In the early to mid-1990s, the average number of new drug patents was 2237 per year. Of these, 500-700 were given United States Adopted Names (USAN) generic names. Of that group, only 220 drugs were in clinical trials in 1995. From 1991 to 1996, FDA approved an average of 31 new drugs per year.

In response to manufacturer and congressional pressure to expedite and simplify the process, the number of drug approvals has been increasing steadily. In 1998, FDA approved 90 new drugs, 30 new molecular entities (drugs never previously marketed in the United States), 124 new or expanded uses of approved drugs, 344 generic drugs, 8 non-prescription drugs, and 9 orphan drugs.4 Approximately 48% of the prescription drugs marketed today have been available only since 1990, contributing to the risk of error.

Market Analysis:

In the early to mid-1990s, the average number of new drug patents was 2237 per year. Of these, 500-700 were given United States Adopted Names (USAN) generic names. Of that group, only 220 drugs were in clinical trials in 1995. From 1991 to 1996, FDA approved an average of 31 new drugs per year. In response to manufacturer and congressional pressure to expedite and simplify the process, the number of drug approvals has been increasing steadily. In 1998, FDA approved 90 new drugs, 30 new molecular entities (drugs never previously marketed in the United States), 124 new or expanded uses of approved drugs, 344 generic drugs, 8 non-prescription drugs, and 9 orphan drugs.4 Approximately 48% of the prescription drugs marketed today have been available only since 1990, contributing to the risk of error.

International symposium and workshops

List of Best International Conferences:

  1. Industrial Pharmacy Conference April 11-12, 2016 Dubai, UAE
  2. Drug Formulation and Bioavailability Congress June 6-8, 2016 Beijing, China
  3. 4th Pharma Congress June 13-15, 2016 Berlin, Germany
  4. Pharma Expo June 20-22,2016 New Orleans, USA
  5. 7th Pharma ConferenceJune 20-22, 2016 New Orleans, USA
  6. Pharma Expo June 20-22, 2016 Capetown, South Africa   
  7. Pharmaceutical Conference and Expo October 08-10, 2015 New Delhi, India
  8. Pharma Expo July 14-16, 2016 Kualalumpur, Malaysia
  9. 6th Pharma Congress July 14-16, 2016 Kualalumpur, Malaysia
  10. Pharma Expo August 29-31, 2016 Sao Paulo, Brazil
  11. 2nd Pharma Middle East Congress October 12-14, 2016 Dubai, UAE
  12. Pharma Marketing Conference November 17-19, 2016 Alicante, Spain
  13. 2nd Parenterals and Injectables Conference October 24-26, 2016 Istanbul, Turkey
  14. 5th Pharmacists Annual Meeting July 11-13, 2016 Brisbane, Australia
  15. 4th GMPGCP & Quality Control Conference October 26-28, 2015 Hyderabad, India
  16. Pharmaceutical Packaging and Labelling Summit, 22 - 23 June, 2016 - UK
  17. 2nd Annual Medical Device and Diagnostic Labeling Conference, 9th – 10th September, 2015, Berlin, Germany
  18. Pharma Packaging and Labeling, 24th – 25th February 2016, Philadelphia, USA
  19. Pharma Packaging and Labeling, 24th – 25th February 2016, Philadelphia, USA
  20. Global Packaging Summit January 25-26, 2016, Belgium
  21. American Packaging Summit April 18-19, 2016, Chicago
  22. Label Expo, EUROPE 2015, 29 September - 2 October
  23. Label Expo, ASIA 1 - 4 December, 2015 China
  24. Label Summit 26 - 27 April, 2015, Las Vegas, USA
  25. Label Expo, 13 - 15 September, 2016, Chicago, USA
  26. Label Expo, 17 - 20 November, Noida, India
  27. PhillyPack, October 7-8, 2015, Philadelphia, PA
  28. TexasPack, October 13-14, 2015, Houston, TX

Relevant Society and Associations

Companies

This page will be updated regularly.

This page was last updated on 14th Sep, 2015

Conferenceseries Destinations

Contact Us

Medical Conferences
Jessie Grace
jessie.grace@conferenceseries.com
1-702-508-5200 Ext:8031, 8041

Pharmaceutical Conferences
Badoni Victor
badoni.victor@conferenceseries.com
1-702-508-5200 Ext:8045, 8047

Immunology & Microbiology Conferences
Walker Smith
walker.smith@conferenceseries.com
1-702-508-5200 Ext:8031

Cancer Conferences
Raul Cliff
raul.cliff@conferenceseries.com
1-702-508-5200 Ext:8039

Nursing and Healthcare Conferences
Jennifer Leny
jennifer.leny@conferenceseries.com
1-702-508-5200 Ext:8044

Diabetes Conferences
Stanley knight
stanley.knight@conferenceseries.com
1-702-508-5200 Ext:8040

Neuroscience Conferences
Sandeep Kumar
sandeep@conferenceseries.com
1-702-508-5200 Ext:8034

Dental Conferences
Raul Cliff
raul.cliff@conferenceseries.com
1-702-508-5200 Ext:8039

Clinical and Biochemistry Conferences
Rohit Casper
rohit.casper@conferenceseries.com
1-702-508-5200 Ext:8033

Biotechnology Conferences
Ravi Vittal
ravi.vittal@conferenceseries.com
1-702-508-5200 Ext:8031, 8037

Material Science Conferences
Lucy Grey
lucygrey@conferenceseries.com
1-702-508-5200 Ext:8035

Genetics & Mol Biology Conferences
Stephen Bruce
stephen.bruce@conferenceseries.com
1-702-508-5200 Ext:8038

Engineering Conferences
Dolly A
dolly@conferenceseries.com
+1-702-508-5200 Ext:8051

Program Enquiries
Symposia/Workshops
Sponsorships
Media Partners | Advertising